ClinicalTrials.gg
Status unknownNCT03438201STRENGTHUpdated Feb 19, 2018

Protein Intake Associated With Physical Activity Related to Specific Outcomes

An interventional study of Intervention and Control in Cancer, Critically Ill and Surgery, sponsored by University of Sao Paulo. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Randomized Controlled Trial . The purpose of this study is to assess the hypothesis that whether a high protein diet combined with a physical activity protocol in surgical cancer patients admitted to the ICU in the post operative period is associated with better physical function at the hospital discharge as well as a better quality of life.

Read the detailed description

Surgical cancer patients will be categorized by their nutritional risk using a specific screening toll. During the hospital stay some measurements will be done. Such as resting energy expenditure (REE) before and after surgery; physical function evaluation; strength and quality of life.

The proposed intervention is a post operative diet with a different amount of protein (diet with a standard amount of protein and a diet with high amount of protein) associated to an institutional protocol of physical activity.

02

Conditions studied

  • Cancer
  • Critically Ill
  • Surgery

Keywords

  • Cancer, ICU, Surgery, Protein, Physical Activity
03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 126 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,035 studies on the registry; 95 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cancer patients
  • Age greater than or equal to 18 years old
  • Have a tendency to be admitted to the ICU after the surgery
  • Fill the eligible criteria to start enteral feeding within 72 hours
  • Sign the consent form;

Exclusion criteria

Exclusion Criteria:

  • Mechanical ventilation such as fraction of inspired oxygen inspired oxygen fraction (FiO2) >60% or positive end expiratory pressure (PEEP) > 12cm H2O
  • Bronchopleural fistula
  • \<50
  • Participant cannot b enrolled in another study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    High-protein diet

    High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol

    Dietary Supplement: Intervention

  • Active comparator
    Normoproteic diet

    Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol

    Dietary Supplement: Control

Interventions

  • Dietary supplementIntervention

    Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day

    Also known as: High Protein intake

  • Dietary supplementControl

    Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day

    Also known as: Standard Protein Intake

06

What researchers measure

Primary outcomes

  1. Physical Function

    6 minutes walk test

    Time frame: 8 days after randomization

Secondary outcomes

  1. Physical Function

    6-minute walk test after 30 days the date of randomization;

    Time frame: 30 days after randomization

  2. Quality of life

    Measurement of quality of life using the Euro-Qol 5D-5L index. EQ-5D-5L index includes five questions concerning mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A summary utility index value can be computed from subject's response to these five questions. Values range from -0.594 (worst possible health score) to 0 (death) to 1.000 (best health).

    Time frame: 6 months after randomization

  3. Body Composition related to prognosis

    Phase Angle (BIA)

    Time frame: 8 days after randomization

  4. Postoperative complications

    Clavien Dindo

    Time frame: 30 days after randomization

  5. Resting Energy Expenditure

    Indirect Calorimetry

    Time frame: one day before surgery and one day after surgery

  6. Length of hospital stay.

    Starts in the first day of hospitalization and ends on the day of hospital discharge

    Time frame: 30 days after randomization

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2018; primary completion for Oct 2018, 6 months later.

Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 6 months is below that.

Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 19, 2018
StartEst.
Apr 4, 2018
Primary completionEst.
Oct 12, 2018
CompletionEst.
Apr 30, 2020
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03438201
Responsible party
Juliano P Almeida, MD, PhD (Medical Doctor, University of Sao Paulo) — Principal investigator
First posted
Feb 19, 2018
Start date
Apr 4, 2018 (estimated)
Primary completion
Oct 12, 2018 (estimated)
Completion
Apr 30, 2020 (estimated)
Last update
Feb 19, 2018

Study contacts

Juliano P Almeida, Professor
Contact
doctorjuliano@yahoo.com.br
(5511) 98149-2592
Ilana Roitman, RD
Contact
ilanaroitman88@gmail.com
(5511) 98322-8123
Juliano P Almeida, Professor
principal investigator · University of Sao Paulo
Ilana Roitman
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion